- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Top 5 AJMC® Articles of September 2018
Here are the top 5 articles for the month of September.
Transcript:
Hi, I’m Jaime Rosenberg for The American Journal of Managed Care®. Here are the top 5 articles for the month of September.
Number 5: An analysis from the Urban Institute found that health insurance coverage gains created by the Affordable Care Act caused the number of uninsured Americans to fall from 17% in 2013 to 10% in 2016.
Number 4: More than half of Americans misused prescription drugs in 2017. While the rate remains unchanged from 2016, there was an observed shift from prescription opioids to other drugs and dangerous drug combinations
Number 3: GlaxoSmithKline’s mepolizumab, marketed as Nucala, is superior to reslizumab and benralizumab for the treatment of eosinophilic asthma, a severe form of asthma that doesn’t respond well to corticosteroids, even at high doses.
Number 2: Researchers have discovered a new subtype of multiple sclerosis that has neuronal loss but no demyelination of the brain’s white matter, suggesting that demyelination and neuronal degeneration occur independently.
Number 1: A study looking at the toxic effects of cancer immunotherapy concluded that the incidence and timing of rare and fatal side effects from immune checkpoint inhibitors remain very low for patients with advanced cancer and should not keep patients from using the therapies.
To read all of these articles and more, visit AJMC.com
Hospital Participation in Medicare ACOs: No Change in Admission Practices and Spending
August 19th 2025Hospital accountable care organization (ACO) participation did not impact emergency department admission rates, length of stay, or costs, suggesting limited effectiveness in reducing spending for unplanned admissions and challenging hospital-led ACO cost-saving strategies.
Read More
Roflumilast Cream 0.05% Durable, Safe for Younger Pediatric Patients
August 15th 2025The INTEGUMENT-OLE study is an open-label extension analysis that followed a primary investigation from the phase 3 INTEGUMENT-PED trial, which investigated the efficacy and safety of once-daily roflumilast cream 0.05% for atopic dermatitis in children aged 2 to 5 years.
Read More
PCPs Have Unique Opportunity to Detect, Manage CKD
August 14th 2025As the prevalence of chronic kidney disease (CKD) continues to rise, empowering primary care providers (PCPs) with the tools, training, and collaborative frameworks needed for optimal management is a public health priority, emphasize the researchers.
Read More
